Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted EPS (Basic) of $1.55 for Q1 2026, up 82.04% on a QoQ basis from $0.85 in Q4 2025, and up 1201.33% year-over-year from $0.12 in Q1 2025.
Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' EPS (Basic) history runs 18 years deep, the most recent figure standing at $1.55 for Q1 2026.
- Quarterly EPS (Basic) rose 1201.33% year-over-year to $1.55 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.09 (up 330.3% YoY) and the FY2025 annual result came in at $2.39, up 209.91% from the prior year.
- EPS (Basic) was $1.55 for Q1 2026 at Alnylam Pharmaceuticals, up from $0.85 in the prior quarter.
- Across five years, EPS (Basic) topped out at $2.23 in Q3 2025 and bottomed at -$3.32 in Q3 2022.
- A 5-year average of -$0.65 and a median of -$0.66 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2025 — EPS (Basic) plunged 280.73% — and 2026, when it surged 1201.33%.
- Alnylam Pharmaceuticals' EPS (Basic) stood at -$1.71 in 2022, then jumped by 35.27% to -$1.1 in 2023, then surged by 40.55% to -$0.66 in 2024, then surged by 229.76% to $0.85 in 2025, then soared by 82.04% to $1.55 in 2026.
- Business Quant data shows ALNY's EPS (Basic) at $1.55 in Q1 2026, $0.85 in Q4 2025, and $2.23 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.55 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 |
| Dec 31, 2025 | 0.85 |
| Sep 30, 2025 | 2.23 |
| Jun 30, 2025 | -0.51 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.66 |
| Sep 30, 2024 | -0.87 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -1.10 |
| Sep 30, 2023 | 1.18 |
| Jun 30, 2023 | -2.21 |
| Mar 31, 2023 | -1.40 |
| Dec 31, 2022 | -1.71 |
| Sep 30, 2022 | -3.32 |
| Jun 30, 2022 | -2.29 |
| Mar 31, 2022 | -2.00 |
| Dec 31, 2021 | -2.18 |
| Sep 30, 2021 | -1.72 |
| Jun 30, 2021 | -1.61 |